tiprankstipranks
Advertisement
Advertisement

PBIGF Stock Latest News

Paradigm Biopharmaceuticals Seeks ASX Quotation for 6.86 Million New Shares
Company AnnouncementsParadigm Biopharmaceuticals Seeks ASX Quotation for 6.86 Million New Shares
2d ago
Paradigm partners with City St George’s to probe osteoarthritis bone lesions
PremiumCompany Announcements
Paradigm partners with City St George’s to probe osteoarthritis bone lesions
8d ago
Paradigm Reaches 50% Enrolment in Global Phase 3 Osteoarthritis Trial
PremiumCompany Announcements
Paradigm Reaches 50% Enrolment in Global Phase 3 Osteoarthritis Trial
10d ago
Paradigm Expands Global Phase 3 Osteoarthritis Trial to Hong Kong and Moldova
PremiumCompany Announcements
Paradigm Expands Global Phase 3 Osteoarthritis Trial to Hong Kong and Moldova
21d ago
Paradigm Biopharmaceuticals Seeks ASX Quotation for 5.65 Million New Shares
PremiumCompany Announcements
Paradigm Biopharmaceuticals Seeks ASX Quotation for 5.65 Million New Shares
25d ago
Paradigm Biopharmaceuticals Widens Half-Year Loss on Intensified Phase 3 Investment
PremiumCompany AnnouncementsParadigm Biopharmaceuticals Widens Half-Year Loss on Intensified Phase 3 Investment
1M ago
Paradigm Biopharmaceuticals Updates Market on Director Paul Rennie’s Equity Holdings
Premium
Company Announcements
Paradigm Biopharmaceuticals Updates Market on Director Paul Rennie’s Equity Holdings
2M ago
Paradigm Biopharmaceuticals Updates Market on Director Option Lapse
Premium
Company Announcements
Paradigm Biopharmaceuticals Updates Market on Director Option Lapse
2M ago
Paradigm’s PPS Shows Sustained Clinical and Structural Benefits in Canine Osteoarthritis Study
PremiumCompany Announcements
Paradigm’s PPS Shows Sustained Clinical and Structural Benefits in Canine Osteoarthritis Study
2M ago
Paradigm Strikes AVet Licensing Deal for Novel Oral Veterinary Osteoarthritis Drug
PremiumCompany Announcements
Paradigm Strikes AVet Licensing Deal for Novel Oral Veterinary Osteoarthritis Drug
2M ago
Paradigm Biopharmaceuticals Director Converts Options Into Shares
PremiumCompany Announcements
Paradigm Biopharmaceuticals Director Converts Options Into Shares
2M ago
Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
PremiumCompany Announcements
Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
2M ago
Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
PremiumCompany AnnouncementsParadigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
2M ago
Paradigm Expands Global Phase 3 Knee Osteoarthritis Trial as Peer-Reviewed Data Bolster iPPS Case
Premium
Company Announcements
Paradigm Expands Global Phase 3 Knee Osteoarthritis Trial as Peer-Reviewed Data Bolster iPPS Case
2M ago
Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
Premium
Company Announcements
Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
2M ago
Paradigm Biopharmaceuticals Seeks ASX Quotation for Nearly 5 Million New Shares
PremiumCompany Announcements
Paradigm Biopharmaceuticals Seeks ASX Quotation for Nearly 5 Million New Shares
3M ago
Paradigm Biopharmaceuticals Flags February 2026 Expiry of 97 Million PAROA Options
PremiumCompany Announcements
Paradigm Biopharmaceuticals Flags February 2026 Expiry of 97 Million PAROA Options
3M ago
Paradigm Nears 25% Recruitment Milestone in Pivotal Knee Osteoarthritis Phase 3 Trial
PremiumCompany Announcements
Paradigm Nears 25% Recruitment Milestone in Pivotal Knee Osteoarthritis Phase 3 Trial
4M ago
Paradigm Biopharmaceuticals’ AGM Resolutions Passed Successfully
PremiumCompany Announcements
Paradigm Biopharmaceuticals’ AGM Resolutions Passed Successfully
5M ago
Paradigm Biopharmaceuticals Secures Additional Funding Through Convertible Notes
PremiumCompany AnnouncementsParadigm Biopharmaceuticals Secures Additional Funding Through Convertible Notes
5M ago
Paradigm Biopharmaceuticals Issues 5 Million Convertible Notes
Premium
Company Announcements
Paradigm Biopharmaceuticals Issues 5 Million Convertible Notes
5M ago
Paradigm Biopharmaceuticals Secures Funding for Global Clinical Expansion
Premium
Company Announcements
Paradigm Biopharmaceuticals Secures Funding for Global Clinical Expansion
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >